Anti-VEGF durability fast facts
- In an IRIS Registry analysis of eyes with neovascular age-related macular degeneration (AMD), about one-third had anti-VEGF injection intervals of less than 8 weeks at the end of year 1. By the end of year 3, 42% had discontinued treatment, defined as no injection for more than 6 months.1
- A 2026 network meta-analysis of 16 studies involving 6,758 patients found no statistically significant differences in best-corrected visual acuity (BCVA) change among aflibercept, ranibizumab, bevacizumab, brolucizumab, and faricimab for neovascular AMD.2
- In PULSAR, 1,011 patients with neovascular AMD were randomized to receive aflibercept 8 mg every 12 or 16 weeks, or 2 mg every 8 weeks. At week 48, both 8-mg regimens were noninferior (+6.7 and +6.2 letters vs. +7.6).3
- In PHOTON, aflibercept 8 mg given every 12 or 16 weeks after 3 monthly loading doses led to noninferior week-48 BCVA gains in diabetic macular edema (DME; +8.8 and +7.9 letters, respectively) compared with aflibercept 2 mg given every 8 weeks after 5 loading doses (+9.2 letters).4
- Aflibercept 8 mg is formulated at 114.3 mg/mL, compared with 40 mg/mL for the 2-mg dose, increasing the injection volume from 0.05 mL to 0.07 mL.5
How aflibercept 8 mg durability holds up outside the protocol
- PULSAR (neovascular AMD): Among patients who completed week 96, 87% in the every-12-week arm had a last assigned interval of at least 12 weeks. In the every-16-week arm, 78%, 53%, and 31% qualified for intervals of at least 16, 20, and 24 weeks, respectively. Through week 96, the mean number of active injections was 9.7 and 8.2 with 8 mg, compared with 12.8 with 2 mg.5
- PHOTON (DME): Among patients completing week 96, 88% (every-12-week arm) and 83% (every-16-week arm) maintained intervals of 12 or more and 16 or more weeks, respectively; 43% and 47% qualified for 20 or more weeks. Mean active injections were 9.5 and 7.8 with 8 mg vs. 13.8 with 2 mg.6
"We have trials where patients are treatment-naive, well treated, and they don't miss many visits compared to our normal population."—Rishi P. Singh, MD, FASRS
Registry durability in treatment-naive and switched eyes
- Treatment-naive eyes reached an injection interval of approximately 12 weeks in both neovascular AMD and DME, with median gains of 4 and 5 letters, respectively, among eyes starting at 20/50 or worse; overall, vision was maintained.7
- Switched neovascular AMD eyes extended their intervals by approximately 2 weeks with stable vision; an expanded cohort of 11,284 switched eyes showed the same median extension, with visual acuity unchanged regardless of the pre-switch interval.7,8
- Switched DME eyes (2,280 eyes; median follow-up, 57 weeks) extended their intervals by a median of 2 weeks, reaching a median of 11.9 weeks with vision maintained. Treatment-naive DME eyes starting at 20/50 or worse gained a median of 5 letters.7,9
"Registry studies capture the broadest kind of group of patients: all the patients who are receiving the drug, not just the patients who met inclusion criteria for a trial and/or were more likely to come in for their visits and be more responsive in a clinical trial."—Jayanth Sridhar, MD
Safety results
"One of the best things we've seen is safety, even though it was not designed to be a safety study, eight milligrams was very safe; it is well-tolerated in the real world."—Jayanth Sridhar, MD